Featured Study Opportunities
The Crohn's & Colitis Foundation utilizes Featured Study Opportunities to collaborate with academic and industry researchers to help enroll patients with Crohn’s disease and ulcerative colitis into clinical studies. The list below highlights our partners' current research studies. Please note that these partners have paid to have their trials posted below. Some partners' studies listed may be recipients of partial or full funding from the Crohn's & Colitis Foundation. This support does not imply recommendation or favor of the Foundation, as the Crohn's & Colitis Foundation does not endorse any particular study.
For a comprehensive listing of all research studies currently recruiting, please click here.
(For e.g NY instead of New York)
Current Results: 84 entries
An Open-Label, Phase 4 Study to Evaluate the Efficacy and Safety of Dual Targeted Therapy with Vedolizumab Intravenous (IV) and Adalimumab Subcutaneous (SC) or Vedolizumab IV and Ustekinumab IV/SC in Moderate to Severe Crohn’s Disease (CD).
The objective of the STENOVA study is to evaluate the safety, pharmacokinetics, and pharmacodynamics of the study drug AGMB-129 in patients with Crohn's disease and symptomatic strictures, and whether it can have a beneficial effect on intestinal strictures.
The purpose of this study is to continuously monitor a patient's IBD biomarkers with the non-invasive IBD Aware wearable device to determine its effectiveness in monitoring IBD inflammation. We also aim to understand how these inflammatory biomarkers relate to your symptoms. By participating, you'll help us enhance the way we monitor and manage IBD.
To our knowledge, the use of a timed modified Mediterranean diet (combining the Mediterranean diet with timed eating) has not been previously investigated in humans. We hypothesise that combining timed eating and the Mediterranean diet will improve inflammation and gut leakiness in patients with IBD as compared to the Mediterranean diet by itself and with no intervention.
The ROSETTA study is a global study assessing the safety and effectiveness of two different doses of the investigational study medicine rosnilimab, compared to placebo, for adults with moderate to severe ulcerative colitis (UC).
The purpose of this study is to evaluate the safety and efficacy of the investigational drug MORF-057 in participants with moderately to severely active Ulcerative Colitis.
To explore the safety, efficacy, effects on quality of life, and biomarker response of ozanimod in participants with moderate to severely active ulcerative colitis (UC).
The Cimzia Pregnancy Exposure Registry is following pregnant women who have been treated with Cimzia during pregnancy and comparing them to pregnant women who were not exposed to Cimzia. Both groups of women and their babies will be followed up to 1 year after delivery. The goal is to determine the possible effect of Cimzia and the diseases it treats on pregnancy and infant outcomes.
We will examine adolescents with newly diagnosed Crohn’s disease at baseline and one year later to evaluate the impact of Crohn’s disease inflammatory activity on bone marrow fat, bone mineral density, bone turnover markers, and to correlate with peripheral blood molecular and immune cell parameters.
The PLANET Study aims to determine the impact of microplastics on intestinal inflammation and the gut microbiome in order to understand the role of this pollutant on the risk of developing IBD as well as other diseases. With this information, the study team hopes to characterize better the role of environmental pollutants on IBD and develop novel strategies towards prevention.
The Featured Study Opportunities page is made possible in part by:
